Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
This 3% reduction is calculated to have a total possible impact of up to $12 billion dollars
Management of type 2 diabetes: new and future developments in treatment
Retatrutide is a next-generation synthetic peptide acting as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Payment is taken only after completing the intake quiz and selecting your medication
The peptide is currently being studied under research protocols and has not yet been approved by the FDA for general medical use
US$ 28.09
US$ 20.62
US$ 26.92
